Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Czechia / NCT07153432
Recruiting Observational

Chronic Kidney Disease Screening

NCT07153432 · tracked via the Priya Life Science Czechia tracker
Sponsor
Institute for Clinical and Experimental Medicine
Phase
Observational
Started
2025-02-24
Last updated
2025-09-04

Condition(s) studied

Chronic Kidney Diseases

Study summary

The goal of this observational study is to assess epidemiology of chronic kidney disease in patients followed at a tertiary care center. The main question it aims to answer is: What is the proportion of patients with chronic kidney disease overall and how many are previously undiagnosed.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * age \> 50 or age \>18 + one of these conditions (history of diabetes, arterial hypertension, ischemic heart disease, stroke, perpheral artery disease, atrial fibrillation, heart failure) * agree to participate * followed at the Institute for Clinical and Experimental Medicine Exclusion Criteria: * unwilling to participate * kidney transplant recipient/previous kidney transplantation

Primary outcome measure(s)

  • Proportion of patients with chronic kidney disease — Baseline
    Chronic kidney disease diagnosed with either decreased estimated glomerular filtration rate and/or increased albumin excretion in urine

Trial sites (1)

FacilityCityRegionStatus
Institute for Clinical and Experimental Medicine Prague Czechia Recruiting

More Institute for Clinical and Experimental Medicine trials in Czechia

Pericoronary Adipocyte Size Gradient Recruiting
Biodegradable Stents in Liver Transplant RecipIents for Treatment of Biliary Anastomotic Strictures Recruiting
Per-oral Endoscopic Myotomy (POEM) in Patients with Postfundplication Dysphagia Starting soon
Continuous Glucose Monitoring in Intensive Care Unit Active, not recruiting
Endoscopic Ultrasound-Guided Radiofrequency Ablation for Pancreatic Cystic Neoplasms and Pancreatic Neuroendocrine Tumors Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07153432 on ClinicalTrials.gov ↗ ← All trials in Czechia